Table 2.
Correlation between CST and BCVA by treatment group in VIBRANT trial. In VIBRANT, patients with macular edema secondary to BRVO received either laser at baseline or IAI 2q4 from baseline through week 24. Both treatment groups received IAI 2q8 from week 24 through week 52. 2q4, 2 mg every 4 weeks; 2q8, 2 mg every 8 weeks; BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; IAI, intravitreal aflibercept injection; r, correlation
| Visit | Laser/IAI | IAI | ||||
|---|---|---|---|---|---|---|
| n | r (95% CI) | P-value | n | r (95% CI) | P-value | |
| Correlation between absolute CST and absolute BCVA | ||||||
| Baseline | 90 | −0.46 (−0.61, −0.27) | < 0.001 | 91 | −0.41 (−0.56, −0.22) | < 0.001 |
| Week 12 | 83 | −0.40 (−0.57, −0.20) | 0.0002 | 88 | 0.13 (−0.08, 0.33) | 0.22 |
| Week 24 | 81 | −0.46 (−0.62, −0.27) | < 0.001 | 83 | 0.14 (−0.08, 0.35) | 0.20 |
| Week 52 | 77 | 0.06 (−0.16, 0.28) | 0.59 | 73 | 0.17 (−0.06, 0.39) | 0.14 |
| Correlation between changes in CST and changes in BCVA | ||||||
| Week 12 | 83 | −0.43 (−0.59, −0.24) | < 0.001 | 88 | −0.34 (−0.51, −0.14) | 0.001 |
| Week 24 | 81 | −0.42 (−0.59, −0.22) | < 0.001 | 83 | −0.32 (−0.50, −0.11) | 0.003 |
| Week 52 | 77 | −0.30 (−0.49, −0.08) | 0.008 | 73 | −0.36 (−0.54, −0.14) | 0.002 |